Clinical trial
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory…
NCT00182650 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00182650 |
|---|---|
| Title | Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma |
| Official title | Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, rituximab, therapeutic autologous lymphocytes, fludarabine phosphate |
| Enrollment | 5 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 29, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: